Axios Science on MSN21d
Mass. files suit accusing insulin makers of price-gougingMassachusetts is the latest state going after insulin makers and the intermediaries officials accuse of price gouging. Why it ...
The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions ...
Campbell’s lawsuit highlights the impact PBMs have on one drug. In Massachusetts, about 500,000 residents are living with diabetes, nearly all of whom rely on the daily use of insulin to survive.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback